PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32314828-0	2020	HCC recurrence in HCV patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs.	Sirolimus	93-102	HCC	Homo sapiens	0-3	
33710804-13	2021	CONCLUSIONS: SNORA23 exhibited antitumor effects in HCC and together with rapamycin, provided a promising therapeutic strategy for HCC treatment.	Sirolimus	74-83	HCC	Homo sapiens	131-134	
24924566-1	2014	OBJECTIVE: To evaluate the influence of sirolimus on the long-term survival of patients after orthotopic liver transplantation (OLT) for hepatocellular carcinoma (HCC).	Sirolimus	40-49	HCC	Homo sapiens	137-167	
24924566-10	2014	CONCLUSION: The sirolimus-based immunosuppressive protocol reduce long-term postoperative recurrence rate and improve the survival rate of patients after OLT for HCC significantly (especially early-mid HCC).	Sirolimus	16-25	HCC	Homo sapiens	162-165	
24924566-10	2014	CONCLUSION: The sirolimus-based immunosuppressive protocol reduce long-term postoperative recurrence rate and improve the survival rate of patients after OLT for HCC significantly (especially early-mid HCC).	Sirolimus	16-25	HCC	Homo sapiens	202-205	
18188819-11	2008	Due to its antiproliferative effects, the immunosuppressive drug sirolimus may play a role for secondary prevention of HCC following transplantation.	Sirolimus	65-74	HCC	Homo sapiens	119-122